The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Genomic profiling of treated high-risk smoldering multiple myeloma
Benjamin Diamond, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses a study which used whole-genome and whole-exome sequencing (WGS; WES) to examine the genomic profile of patients with high-risk smoldering multiple myeloma (HR-SMM) treated with two distinct regimens. Dr Diamond summarizes the results of this study and further comments on the importance of using genomic information to better understand which patients are truly high-risk, and prevent the over- or under-treatment of patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen, Sanofi: honoraria
